nmCRPC VL

ARAMIS Trial: Darolutamide Demonstrates Improved Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) - Fred Saad

Details
Fred Saad provides his perspective on the newest ARAMIS trial results, presented at ASCO 2020. Results from the phase III androgen receptor inhibiting agent for metastatic-free survival (ARAMIS) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a significant improvement in delaying the time to death in patients receiving darolutami...

Treatment Advances in Non-Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu joins Alicia Morgans to discuss treatment advances in the non-metastatic castration-resistant prostate cancer space, focusing on the data and clinical implications of the ARAMIS trial. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies, as well as...

Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore

Details
In this conversation with Alicia Morgans, Neal Shore talks about the three new approved agents in the non-metastatic, castration-resistant prostate cancer (CRPC) setting; apalutamide, enzalutamide, and darolutamide and specifically highlight the urge for findings of prolonged survival, which have now been reported from both enzalutamide in the PROSPER trial and darolutamide in the ARAMIS trial. To...

Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi

Details
Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...

Considerations for the Treatment of Non Metastatic Castration-Resistant Prostate Cancer - An Interview with Maha Hussain and Tia Higano

Details
Tia Higano and Maha Hussain share highlights of their 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentations with Alicia Morgans. Drs. Higano and Hussain presented opposing presentations on the pros and cons of treatment in the nonmetastatic castration-resistant prostate cancer setting. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in t...

Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial - Interview with Nicholas James

Details
Nick James and Alicia Morgans talk about the newly presented STAMPEDE data just released and presented at the 2019 ESMO meeting including, long-term follow-up of the docetaxel patients as well as the much anticipated metastatic data. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncolo...

Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad

Details
Fred Saad joins Alicia Morgans to discuss the quality of life data from the ARAMIS trial. The data suggest that adding darolutamide (systemic therapy) to ADT compared to ADT alone improves quality fo life in the patients, and these include bowel and urinary symptom benefit along with the skeletal outcomes and quality-of-life measures. The ARAMIS study suggests that androgen receptor antagonist dar...

ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life - Karim Fizazi

Details
Karim Fizazi and Alicia Morgans discuss a follow-up on the quality of life parameters evaluated in the ARAMIS trial. Darolutamide was also associated with benefits with regard to all secondary end points, including overall survival, time to pain progression, time to cytotoxic chemotherapy, and time to a symptomatic skeletal-related event. The incidence of adverse events that occurred or worsened d...

Darolutamide Demonstrates Efficacy and Safety in Men with nmCRPC - Neeraj Agarwal

Details
Petros Grivas discussed Neeraj Agarwal's insights about the latest prostate cancer study results that will impact patient care as presented at ASCO GU 2019. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under develop...

ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC - Karim Fizazi

Details
Karim Fizazi discusses the efficacy and safety of darolutamide with Alicia Morgans. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer (nmCRPC). Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. In total, 1509 patien...